Figure 8
Anti-HCV activity of IFNα2b and chimeric proteins. The percentage reduction in HCV titer by latent and activated: (A) IFNα2b-NS3-LAP fusion proteins; (B) LAP-NS3-IFNα2b fusion proteins and (C) unconjugated recombinant IFNα2b. The latent fusion proteins showed approximately 25% reduction in viral load at the concentration of 0.5 ng/ml and maximum 29% (for IFNα2b-NS3-LAP) and 26% (for LAP-NS3-IFNα2b) reduction in HCV viral titer at 100 ng/ml. Pre-activated and real time activated fusion protein showed 50% reduction in viral titer at concentration of ~1.0 ng/ml. The standard IFNα2b showed EC50 against HCV at 0.4 ng/ml.
